[Clinical and experimental bases for using dibasol in inflammatory diseases of the maxillofacial area].
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use*; D002481:Cellulitis / Q000188:drug therapy; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005145:Face; D005260:Female; D005491:Focal Infection, Dental / Q000188:drug therapy; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007571:Jaw Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy; D051381:Rats; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D001562:Benzimidazoles; C004453:bendazole
Klniko-éksperimental'noe obosnovanie primeneniia dibazola pri vospalitel'nykh zabolevaniiakh cheliustno-litsevoĭ oblasti.